Exelixis focuses on future growth despite COSMIC-313 trial challenges
Genitourinary Cancer Symposium 2025, held on 13-15 February, final results from the randomised, multicentre, double-blind, ...
Healio16h
VIDEO: Trial builds on current microsatellite instability-high colorectal cancer therapy
In this video, Arvind N. Dasari, MD, MS, discussed the results of the CheckMate 8HW trial in which nivolumab and ipilimumab were compared with nivolumab monotherapy for microsatellite instability-high ...
stocknews20h
3 Healthcare Stocks Tackling America’s Biggest Medical Challenges
From breakthrough treatments to AI-driven diagnostics, healthcare is evolving faster than ever. With increasing healthcare ...
JD Supra2h
Life Sciences Under the Microscope: Key 2024 Takeaways and What’s Ahead for 2025
The life sciences industry experienced a dynamic year in 2024. As the public markets gained traction, IPO activity and venture investment saw ...
Hosted on MSN5h
The Artificial Intelligence Party Over for Now? Safe 4%+ High-Yield Dividend Blue Chips Are On Sale
Dividend stocks are a favorite among investors for good reason. They provide a steady income stream of passive income and ...
Yahoo Finance22h
Exelixis, Inc. (EXEL)
Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors have been highlighted in this Screen of The Week article. ALAMEDA, Calif., February 25, 2025--Exelixis, Inc. (Nasdaq: EXEL) today ...